[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA202091478A1 - Антитела - Google Patents

Антитела

Info

Publication number
EA202091478A1
EA202091478A1 EA202091478A EA202091478A EA202091478A1 EA 202091478 A1 EA202091478 A1 EA 202091478A1 EA 202091478 A EA202091478 A EA 202091478A EA 202091478 A EA202091478 A EA 202091478A EA 202091478 A1 EA202091478 A1 EA 202091478A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alpha
synuclein
antibodies
fibrils
present
Prior art date
Application number
EA202091478A
Other languages
English (en)
Inventor
Ральф Адамс
Патрик Дауни
Теренс Сьюард Бейкер
Керри Луиз Тайсон
Лоренцо Де Лихтервельде
Дэниел Джон Лайтвуд
Дэвид Джеймс Макмиллан
Original Assignee
Юсб Биофарма Срл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юсб Биофарма Срл filed Critical Юсб Биофарма Срл
Publication of EA202091478A1 publication Critical patent/EA202091478A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Настоящее изобретение относится к связывающим альфа-синуклеин антителам и их фрагментам, способным связывать альфа-синуклеин в виде мономера или в фибриллах и предотвращать агрегацию альфа-синуклеина, индуцированную фибриллами альфа-синуклеина. Антитела по настоящему изобретению предназначены для применения для лечения синуклеинопатий, включая болезнь Паркинсона.
EA202091478A 2017-12-15 2018-12-13 Антитела EA202091478A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1720975.0A GB201720975D0 (en) 2017-12-15 2017-12-15 Anti-alpha synuclein antibodies
PCT/EP2018/084697 WO2019115674A1 (en) 2017-12-15 2018-12-13 Anti-alpha-synuclein antibodies

Publications (1)

Publication Number Publication Date
EA202091478A1 true EA202091478A1 (ru) 2020-09-04

Family

ID=61009086

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091478A EA202091478A1 (ru) 2017-12-15 2018-12-13 Антитела

Country Status (25)

Country Link
US (2) US11261242B2 (ru)
EP (1) EP3724224A1 (ru)
JP (2) JP7292279B2 (ru)
KR (1) KR20200099160A (ru)
CN (1) CN111479826B (ru)
AR (1) AR115192A1 (ru)
AU (1) AU2018382530A1 (ru)
BR (1) BR112020010504A2 (ru)
CA (1) CA3083199A1 (ru)
CL (1) CL2020001605A1 (ru)
EA (1) EA202091478A1 (ru)
EC (1) ECSP20039623A (ru)
GB (1) GB201720975D0 (ru)
IL (1) IL275187A (ru)
MA (1) MA51135A (ru)
MX (1) MX2020005691A (ru)
PE (1) PE20201061A1 (ru)
PH (1) PH12020551007A1 (ru)
SG (1) SG11202004502SA (ru)
TN (2) TN2020000069A1 (ru)
TW (2) TWI801469B (ru)
UA (1) UA126295C2 (ru)
UY (1) UY38010A (ru)
WO (1) WO2019115674A1 (ru)
ZA (2) ZA202003542B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110506057B (zh) 2017-02-17 2023-09-29 百时美施贵宝公司 Alpha突触核蛋白抗体及其应用
CA3111907A1 (en) * 2018-10-19 2020-04-23 Janssen Vaccines & Prevention B.V. Anti-synuclein antibodies
AU2020350769A1 (en) * 2019-09-20 2022-03-31 Denali Therapeutics Inc. Anti-alpha-synuclein antibodies and methods of use thereof
WO2021113464A1 (en) * 2019-12-04 2021-06-10 Friedman Simon Protein blocking assembly and methods of making and using

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
JP4055579B2 (ja) 2000-12-13 2008-03-05 大正製薬株式会社 新規抗体
EP1572894B1 (en) 2001-11-21 2016-04-13 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha synuclein, or polyglutamine repeats for induction of an immune response thereto
US8697082B2 (en) 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
PL1633189T3 (pl) 2003-05-19 2017-12-29 Prothena Biosciences Limited Skrócone fragmenty alfa-synukleiny w chorobie z ciałami lewy'ego
US7674599B2 (en) 2003-11-08 2010-03-09 Elan Pharmaceuticals, Inc. Methods of using antibodies to detect alpha-synuclein in fluid samples
EA013752B1 (ru) 2004-08-09 2010-06-30 Элан Фармасьютикалз, Инк. Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
WO2007021255A1 (en) 2005-08-09 2007-02-22 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
HUE043966T2 (hu) 2007-02-23 2019-09-30 Prothena Biosciences Ltd Szinukleinopátiás és amiloidogén betegség megelõzése és kezelése
EP2118300B1 (en) 2007-02-23 2015-05-27 Prothena Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
JP5747414B2 (ja) 2008-04-29 2015-07-15 バイオアークティック ニューロサイエンス アーベー α−シヌクレイン関連疾患についての治療および診断方法における使用のための抗体およびワクチン
US8940276B2 (en) 2008-12-19 2015-01-27 Biogen Idec International Neuroscience Gmbh Human anti-alpha-synuclein antibodies
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
RS57029B1 (sr) 2010-02-26 2018-05-31 Bioartic Ab Protofibril-vezujuća antitela i njihova upotreba u terapeutskim i dijagnostičkim postupcima za parkinsonovu bolest, demenciju sa levi telima i drugim alfa-sinukleinopatijama
EP2366714A1 (en) 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
EP2635907A4 (en) 2010-11-05 2014-04-16 Univ Brandeis ALPHA-SYNUCLEINE CLIVED ICE AS A BIOLOGICAL MARKER
DE102011008153B4 (de) 2011-01-08 2018-08-09 Aj Roboscreen Gmbh Verfahren zur Herstellung eines monoklonalen Antikörpers gegen oligomeres Alpha-Synuclein
EP2723379B1 (en) 2011-06-23 2018-09-12 Biogen International Neuroscience GmbH Anti-alpha synuclein binding molecules
RS57315B1 (sr) * 2011-10-28 2018-08-31 Prothena Biosciences Ltd Humanizovana antitela koja prepoznaju alfa-sinuklein
KR102086061B1 (ko) 2012-01-27 2020-03-11 프로테나 바이오사이언시즈 리미티드 알파-시누클레인을 인식하는 인간화된 항체
DK2857419T3 (da) 2012-05-30 2021-03-29 Chugai Pharmaceutical Co Ltd Antigen-bindende molekyle til eliminering af aggregerede antigener
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US9534044B2 (en) 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
WO2015051159A1 (en) 2013-10-02 2015-04-09 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
EP3071974A2 (en) 2013-11-19 2016-09-28 Prothena Biosciences Limited Monitoring immunotherapy of lewy body disease from constipation symptoms
PL3071597T3 (pl) 2013-11-21 2020-11-30 F.Hoffmann-La Roche Ag Przeciwciała przeciwko alfa-synukleinie i sposoby stosowania
WO2015155694A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
US10155030B2 (en) 2014-05-23 2018-12-18 University Of South Florida Methods, antibodies, and vaccines utilizing epitopes of alpha synuclein for treatment of parkinsons disease
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
ES2953855T3 (es) 2014-09-11 2023-11-16 Univ Texas Detección de proteínas mal plegadas
WO2016040905A1 (en) 2014-09-11 2016-03-17 Board Of Regents Of The University Of Texas System Detection of misfolded alpha synuclein protein
WO2016040903A1 (en) 2014-09-11 2016-03-17 Board Of Regents Of The University Of Texas System Detection of misfolded amyloid beta protein
EP3207057A2 (en) 2014-10-16 2017-08-23 F. Hoffmann-La Roche AG Anti-alpha-synuclein antibodies and methods of use
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
DK3341725T3 (da) 2015-08-25 2021-09-06 Prothena Biosciences Ltd Fremgangsmåder til detektering af phosphoryleret alpha-synuklein
AU2016361350B2 (en) 2015-11-23 2023-04-06 Sangamo Therapeutics, Inc. Methods and compositions for engineering immunity
WO2017176835A2 (en) 2016-04-06 2017-10-12 Imago Pharmaceuticals, Inc. Therapeutic antibodies for treatment of neurodegeneration
MD3463435T2 (ro) 2016-06-02 2022-03-31 Medimmune Ltd Anticorpi impotriva alfa sinucleinei și utilizări ale acestora
GB201611840D0 (en) 2016-07-07 2016-08-24 Univ Court Of The Univ Of Edinburgh The Alpha-synuclein detection assay
WO2018039147A1 (en) 2016-08-23 2018-03-01 The Johns Hopkins University THERAPEUTIC USES OF LAG3 THE α-SYNUCLEIN TRANSMISSION RECEPTOR
CN109937210B (zh) 2016-11-15 2023-09-15 H.隆德贝克有限公司 用于治疗共核蛋白病的药剂、用途和方法
US20180134776A1 (en) 2016-11-17 2018-05-17 United Arab Emirates University Alpha-Synuclein Antibodies (4H6)
US20180134777A1 (en) 2016-11-17 2018-05-17 United Arab Emirates University Alpha-Synuclein Antibodies (11D12)
US20180134775A1 (en) 2016-11-17 2018-05-17 United Arab Emirates University Alpha-Synuclein Antibodies (7A11)
JP2020511963A (ja) 2016-12-12 2020-04-23 ザ マイケル ジェイ． フォックス ファウンデーション フォー パーキンソンズ リサーチ ヒトアルファ−シヌクレインに対する抗体
US11325968B2 (en) 2016-12-16 2022-05-10 H. Lundbeck A/S Alpha-synuclein antibodies
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
AU2018206279B2 (en) 2017-01-06 2020-09-03 Abl Bio Inc. Anti-alpha-syn antibody and use thereof
JP2020504151A (ja) 2017-01-09 2020-02-06 カリフォルニア インスティチュート オブ テクノロジー パーキンソン病の診断および治療薬における腸内微生物叢の使用
CN110506057B (zh) 2017-02-17 2023-09-29 百时美施贵宝公司 Alpha突触核蛋白抗体及其应用
JOP20190227A1 (ar) 2017-03-31 2019-09-30 Biogen Int Neuroscience Gmbh تركيبات وطرق لعلاج اعتلالات السينوكلين
IL270612B1 (en) 2017-05-16 2024-10-01 Amprion Inc Discovery of misfolded tau protein
WO2018237338A1 (en) 2017-06-23 2018-12-27 Denali Therapeutics Inc. ANTI-ALPHA-SYNCUCIN ANTIBODIES AND METHODS OF USE

Also Published As

Publication number Publication date
CL2020001605A1 (es) 2020-08-28
JP7292279B2 (ja) 2023-06-16
MX2020005691A (es) 2020-08-20
ECSP20039623A (es) 2020-08-31
SG11202004502SA (en) 2020-06-29
TWI801469B (zh) 2023-05-11
JP2021509012A (ja) 2021-03-18
GB201720975D0 (en) 2018-01-31
TN2020000069A1 (en) 2022-01-06
ZA202003542B (en) 2022-12-21
PE20201061A1 (es) 2020-10-16
UY38010A (es) 2019-07-31
UA126295C2 (uk) 2022-09-14
AU2018382530A1 (en) 2020-06-18
CA3083199A1 (en) 2019-06-20
BR112020010504A2 (pt) 2020-11-24
WO2019115674A1 (en) 2019-06-20
AR115192A1 (es) 2020-12-09
EP3724224A1 (en) 2020-10-21
JP2023127585A (ja) 2023-09-13
RU2020123274A (ru) 2022-01-17
TW202332692A (zh) 2023-08-16
PH12020551007A1 (en) 2021-08-16
RU2020123274A3 (ru) 2022-01-17
TW201930354A (zh) 2019-08-01
US11261242B2 (en) 2022-03-01
IL275187A (en) 2020-07-30
MA51135A (fr) 2021-03-24
CN111479826B (zh) 2024-10-29
CN111479826A (zh) 2020-07-31
ZA202103456B (en) 2023-01-25
US20220220192A1 (en) 2022-07-14
KR20200099160A (ko) 2020-08-21
TN2021000169A1 (en) 2023-04-04
US20210107971A1 (en) 2021-04-15

Similar Documents

Publication Publication Date Title
EA202091482A1 (ru) Антитела
MX2023014569A (es) Anticuerpos anti-sirpa.
ZA201801083B (en) Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
MX2019009117A (es) Anticuerpos anti alfa-sinucleina y usos de los mismos.
EA201890143A2 (ru) Антитела против pdgfr-бета и их применения
PH12020551007A1 (en) Anti-alpha-synuclein antibodies
EA201790377A1 (ru) Антитела к глюкагону и их применения
EA201890315A1 (ru) Молекулы антител, связывающие cd22
EA201591839A1 (ru) Терапевтические пептиды
EA201692109A1 (ru) Варианты антител к фактору d и их применение
UA117096C2 (uk) Поліпептид, що зв'язується з c5 комплементу людини
EA201790305A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
EA202193038A1 (ru) Антитела против sema3a и их применения для лечения заболеваний глаз
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
EA202190045A1 (ru) Составы/композиции, содержащие ибрутиниб
EA201991395A1 (ru) Новые композиции для лечения суставных нарушений
EA201992604A1 (ru) Полинуклеотиды aadc для лечения болезни паркинсона
EA201991504A1 (ru) Композиции на основе аминокислот и способы лечения заболеваний и нарушений мышц
EA201892675A1 (ru) Фармацевтическая композиция, содержащая этеплирсен
EA202091619A3 (ru) Антитела против tigit